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A	  series	  of	  discoveries	  has	  transformed	  concepts	  of	  spondyloarthritis	  and	  pro-­‐inflammatory	  cytokine	  
interleukin-­‐23	   (IL-­‐23)	   has	   taken	   center	   stage.	   The	   IL-­‐23	   frenzy	   kicked	   off	  with	   the	   identification	   of	  
SNPs	  in	  the	  IL-­‐23	  receptor	  (IL23R)	  gene	  that	  are	  associated	  with	  ankylosing	  spondylitis	  (AS)	  1	  and	  also	  
with	  related	  disorders	  such	  as	  psoriasis,	  psoriatic	  arthritis	  and	  Crohn’s	  disease.	  	  The	  most	  striking	  and	  
direct	   evidence	   comes	   from	   an	   in	   vivo	   IL-­‐23	   overexpression	   study	   in	   mice	   that	   phenocopies	   the	  
human	   disease	   and	   its	   Janus-­‐faced	   characteristics:	   joint	   inflammation	   and	   structural	   damage	  
presenting	  as	  new	  bone	  formation2.	  Patient	  studies	  reported	  increased	  serum	  levels	  of	  IL-­‐23	  in	  AS	  	  3-­‐5	  
and	  presence	  of	  IL-­‐23	  positive	  cells	  was	  shown	  in	  facet	  joints	  of	  AS	  patients6.	  Direct	  clinical	  evidence	  
comes	   from	   a	   prospective,	   open-­‐label	   clinical	   trial	   with	   ustekinumab,	   an	   antibody	   binding	   to	   the	  
shared	   p40	   subunit	   of	   IL-­‐23	   and	   IL-­‐12	   7	   and	   successful	   clinical	   trials	   targeting	   IL-­‐17,	   one	   of	   the	  
downstream	  cytokines	  associated	  with	  IL-­‐23	  signaling8.	  Key	  to	  the	  hypothesis	  and	  evidence	  proposed	  
in	  the	  mouse	  model,	  is	  the	  presence	  of	  an	  IL-­‐23	  receptor	  positive	  T-­‐cell	  population	  in	  the	  enthesis	  of	  
mice.	  	  As	  enthesitis	  is	  one	  of	  the	  main	  characteristics	  of	  AS	  and	  was	  proposed	  as	  the	  primary	  lesion9,	  
it	   is	   hard	   to	   ignore	   the	   potential	   key	   role	   of	   such	   cells.	   However,	   until	   now,	   these	   IL-­‐23	   receptor	  
positive	  cells	  have	  not	  yet	  been	  demonstrated	  in	  human	  samples.	  	  
	  
In	  this	  issue	  of	  ARD,	  Ciccia	  and	  colleagues	  report	  on	  the	  presence	  of	  a	  population	  of	  IL-­‐23R	  positive	  
innate	   lymphoid	   cells	   (ILCs)	   in	   the	   gut,	   peripheral	   blood,	   synovial	   fluid	   and	   bone	   marrow	   of	   AS	  
patients10.	  Numbers	  of	  such	  cells	  are	   increased	  as	  compared	  to	  different	  controls	  and	  their	  surface	  
characteristics	   show	   similarities	  with	   the	  mouse	   cells	   identified	   earlier.	   However,	   these	   ILCs	   are	   a	  
rare	  cell	  type	  whose	  significance	  in	  human	  disease	  is	  as	  yet	  uncertain.	  In	  two	  previous	  studies	  Ciccia	  
et	  al	  showed	  increased	  IL-­‐23	  expression	  in	  the	  gut	  of	  AS	  patients	  as	  compared	  to	  healthy	  controls11,12.	  
In	   AS	   synovium	   and	   peripheral	   blood	   cells	   however,	   no	   differences	   in	   expression	   of	   IL-­‐23	   were	  
found13,14.	  
	  
They	  characterized	  these	  cells	  as	  Lyn-­‐IL-­‐23R+NKp44+Tbet+RORc-­‐	  cells	  and	  their	  induced	  production	  of	  
cytokines	  IL-­‐17	  and	  IL-­‐22	  led	  them	  to	  conclude	  these	  are	  ILC3	  cells.	  Unlike	  conventional	  ILC3	  and	  IL-­‐
23R+	  entheseal	  T	   cells,	   these	  cells	   seemingly	  do	  not	  express	  RORc	  but	  do	  express	   the	   transcription	  
factor	   Tbet	   which	   can,	   according	   to	   the	   authors,	   possibly	   be	   explained	   by	   a	   specific	   stage	   of	  
differentiation	  of	  these	  cells.	  This	  finding	  makes	  them	  somewhat	  atypical,	  even	  for	  ILC3s.	  The	  reasons	  
of	   these	   differences	   between	   ‘conventional’	   characteristics	   of	   ILCs	   and	   the	   spondyloarthritis’	  
associated	  cells	  are	  unclear	  and	  whether	  these	  changes	  precede	  onset	  of	  inflammation	  or	  are	  rather	  
a	  secondary	  to	  already	  established	   inflammation	  remains	  to	  be	  determined.	  Further	  clarification	  of	  
the	   exact	   nature	   of	   these	   cells	   clearly	   needs	   to	   be	   carried	   out.	   Hence,	   fine	   details	   in	   small	  
subpopulations	  of	  cells	  but	  may	  still	  represent	  a	  static	  rather	  than	  dynamic	  view	  on	  cell	  populations	  
that	  are	  actively	  part	  of	  host	  defense	  or	  disease.	  
	  
The	   expansion	   of	   these	   ILC3	   cells	   in	   AS	   patients	   with	   acute	   and	   chronic	   gut	   inflammation	   was	  
significantly	   correlated	  with	   the	  disease	  activity	  as	  assessed	  by	   the	  BASDAI.	   In	  AS	  patients	  without	  
gut	   inflammation	   the	   upregulation	   of	   ILC3s	   was	   not	   detected.	   The	   authors	   not	   only	   reported	   an	  
expansion	  of	  NKp44+ILC3s	   in	  gut	   samples	  of	  AS	  patients,	  but	  also	   in	   the	  peripheral	  blood,	   synovial	  
fluid	   and	   the	   bone	   marrow	   of	   AS	   patients.	   ILC3s	   are	   defined	   by	   their	   capacity	   to	   produce	   the	  
interleukins	  IL-­‐17	  and	  IL-­‐2215,	  portrayed	  as	  critical	  cytokines	  in	  the	  pathogenesis	  of	  AS.	  In	  the	  study,	  
gut	   ILC3	   cells	   were	   demonstrated	   to	   produce	   IL-­‐17	   and	   IL-­‐22	   and	   a	   small	   percentage	   of	   cells	  
expressed	  both	  cytokines.	   In	   the	  peripheral	  blood,	   the	  majority	  of	   ILC3s	  produced	   IL-­‐22	  and	  only	  a	  
small	  subset	  of	  ILC3s	  produced	  IL-­‐17	  or	  the	  combination	  of	  IL-­‐22	  and	  IL-­‐17.	  	  Among	  synovial	  fluid	  and	  
bone	   marrow	   mononuclear	   ILC3s	   produced	   exclusively	   IL-­‐22.	   The	   reasons	   for	   these	   differential	  
patterns	   according	   to	   localization	  are	  unclear	   and	   could	   reflect	   tissue	   imprinted	   cytokine	  patterns.	  
These	  data	  suggest	  ILCs	  could	  be	  an	  important	  supplier	  of	  IL-­‐17	  and	  IL-­‐22	  in	  AS,	  which	  is	  also	  one	  of	  
the	  implicit	  conclusions	  of	  this	  study	  by	  Ciccia	  et	  al.	  
	  
Insights	  into	  the	  role	  of	  IL-­‐17	  in	  spondyloarthritis	  are	  dynamically	  evolving	  with	  a	  shift	  from	  a	  focus	  
on	  adaptive	  immune	  cells	  towards	  more	  innate	  immune	  populations.	   Indeed,	  IL-­‐17	  producing	  CD4+	  
cells,	   also	   known	   as	   Th17	   cells,	  were	   shown	   to	   be	   elevated	   in	  HLA-­‐B27/human	  beta2m	   transgenic	  
rats16	  and	  in	  the	  lymph	  nodes	  of	  an	  AS	  mouse	  model17.	  Moreover,	  there	  are	  studies	  demonstrating	  
an	   increased	   amount	   of	   IL-­‐17	   producing	   CD4+	   cells	   in	   the	   blood	   of	   AS	   patients	   as	   compared	   to	  
controls18-­‐21	  albeit	  that	  this	  observation	  is	  not	  consistent	  22-­‐24.	  	  IL-­‐17	  producing	  cells	  were	  also	  found	  
in	   the	   subchondral	   bone	   marrow	   cells	   of	   affected	   facet	   joints	   of	   AS	   patients6.	   Interestingly,	   the	  
majority	  of	  these	  IL17	  positive	  cells	  were	  rather	  innate	  immune	  cells	  (CD15+	  neutrophils	  and	  MPO+	  
cells	  of	  the	  myeloid	  lineage)	  than	  CD4+	  T	  cells6.	  Obviously,	  the	  most	  convincing	  proof	  of	  principle	  that	  
IL-­‐17	   plays	   a	   key	   role	   in	   spondyloarthritis	   is	   found	   in	   the	   clinical	   trials	   evaluating	   the	   effect	   of	  
secukinumab,	  a	  monoclonal	  anti-­‐IL17A	  antibody	  that	  rapidly	  reduced	  clinical	  and	  biological	  signs	  of	  
active	  ankylosing	  spondylitis8.	  	  
	  
IL-­‐22	   has	   also	   earned	   its	   place	   in	   the	   spotlights	   as	   it	   has	   not	   only	   been	   associated	   with	  
enthesitis/arthritis	  development	   in	  mice	  but	  also	  with	  upregulation	  of	  genes	  potentially	   involved	   in	  
the	  new	  bone	   formation	  process	   (such	  as	  Wnts	  and	  bone	  morphogenetic	  proteins)2.	  However,	   the	  
role	  for	  IL-­‐22	  in	  AS	  and	  related	  disorders	  seems	  to	  be	  tissue	  dependent	  -­‐	  as	  demonstrated	  in	  a	  study	  
by	  Benham	  et	  al	  using	   the	  SKG	  mouse	  model25.	   In	   this	  mouse	  model	  curdlan	   injection	   in	  SKG	  mice	  
leads	  to	  IL-­‐23	  dependent	  axial	  and	  peripheral	  arthritis	  and	  ileitis.	  When	  IL-­‐22	  was	  neutralized	  by	  an	  
IL-­‐22	  antibody,	   the	  mice	  developed	  a	  reduced	  severity	  of	  enthesitis	  but	  an	  exacerbation	  of	   ileitis25.	  
This	   finding	   highlights	   that	   the	   effects	   of	   interleukins	   in	   the	   pathogenesis	   of	   AS	   are	   not	   always	  
straight	   forward,	   but	   can	   vary	   from	   tissue	   to	   tissue	   and	   influenced	   by	   tissue	   dependent	  
environmental	  factors.	  It	  is	  important	  to	  note	  that	  the	  current	  attention	  towards	  IL-­‐23,	  IL-­‐17	  and	  IL-­‐
22	   somewhat	   neglects	   the	   critical	   role	   of	   tumor	  necrosis	   factor	   (TNF)	   in	   this	   type	  of	   diseases.	  Not	  
only	   does	   a	   TNF	  overexpression	  model	  mimic	  many	   features	   of	   the	   disease26	   but	   TNF	   inhibition	   is	  
currently	   the	   mainstay	   approach	   with	   high	   and	   sustained	   efficacy	   in	   SpA.	   Bringing	   together	   the	  
different	  proinflammatory	  cytokines	  in	  one	  paradigm	  is	  therefore	  an	  interesting	  challenge.	  	  
	  
Detailed	  histological	  analysis	  of	  the	  gut	  biopsies	  drives	  the	  authors	  to	  propose	  the	  hypothesis	  that	  IL-­‐
23	   receptor	  positive	   ILC3s	  differentiate	   in	   the	   gut	   and	   then	  migrate	   to	   extra-­‐intestinal	   sites	  where	  
they	  produce	  IL-­‐17	  and	  IL-­‐22.	  	  This	  hypothesis	  was	  formulated	  in	  part	  on	  the	  abundant	  expression	  of	  
α4β7	   integrin	   on	   ILC3s,	   a	   β7	   integrin	   with	   marked	   gut	   tropism,	   even	   though	   earlier	   work	  
demonstrated	   it	  presence	  on	  synovial	  T	  cells	   in	  SpA	  synovium27. 	  Although	  this	  hypothesis	   touches	  
the	  limits	  of	  careful	  observation	  in	  human	  samples	  without	  additional	  mechanistic	  experiments,	  the	  
concept	  is	  certainly	  worth	  considering.	  Moreover,	  earlier	  this	  year	  Mackley	  et	  al	  provided	  the	  first	  in	  
vivo	  evidence	  of	  ILC3	  traffic	  starting	  from	  the	  gut	   in	  mice28.	  The	  concept	  is	  also	  in	   line	  with	  old	  and	  
new	  insights	  into	  the	  role	  of	  gut	  inflammation	  in	  spondyloarthritis.	  Five	  to	  10%	  of	  AS	  patients	  suffer	  
from	  clinically	  apparent	  inflammatory	  bowel	  disease	  (IBD)	  and	  even	  a	  much	  larger	  proportion	  of	  AS	  
patients	  suffer	  from	  subclinical	  gut	  inflammation	  as	  already	  suggested	  in	  198529.	  	  In	  a	  recent	  study	  by	  
Van	  Praet	  et	  al	  46.2%	  of	  AS	  patients	  showed	  microscopic	  gut	  inflammation	  of	  which	  16.9%	  was	  acute	  
and	  29.2%	  was	  chronic	  inflammation30.	  	  AS	  patients	  with	  chronic	  gut	  inflammation	  also	  have	  a	  higher	  
degree	   of	   bone	   marrow	   edema,	   as	   seen	   on	   MRI	   further	   supporting	   a	   link	   between	   mucosal	  
inflammation	  and	  progressive	  disease	  in	  AS31.	  The	  gut	  is	  a	  barrier	  tissue	  continuously	  faced	  with	  the	  
challenge	   of	   maintaining	   the	   symbiotic	   gut	  microbiome	  while	   avoiding	   local	   and	   systemic	   disease	  
development	  by	  pathogenic	  microorganisms.	  New	  technologies	  can	  assess	  the	  gut	  microbiome	  in	  a	  
systematic	  way.	  Different	   efforts	   are	   underway	   to	   link	   the	  microbiome	  with	   gut	   inflammation	   and	  
joint	  disease	  in	  SpA	  and	  the	  results	  are	  eagerly	  awaited.	  	  	  
	  
ILC3s	  are	  required	  for	  human	  immunity	  against	  extracellular	  bacteria	  and	  also	  play	  a	  role	  in	  chronic	  
inflammation	  due	   to	   its	  pro-­‐inflammatory	  characteristics15.	  Keeping	   in	  mind	  that	   intestinal	  bacteria	  
could	  play	  a	  role	  in	  the	  pathogenesis	  of	  AS,	  as	  described	  above,	  and	  that	  AS	  is	  a	  chronic	  inflammatory	  
disease,	  the	  hypothesis	  that	  ILC3s	  are	  directly	  involved	  in	  the	  pathogenesis	  of	  AS	  sounds	  plausible.	  Of	  
course,	  further	  research	  is	  necessary	  to,	  firstly,	  confirm	  the	  data	  and,	  secondly,	  further	  explore	  this	  
hypothesis.	  If	  the	  hypothesis	  about	  the	  migration	  of	  IL-­‐23	  sensitized	  gut-­‐resident	  ILC3s	  is	  correct,	  one	  
of	  the	  key	  residual	  questions	  for	  example	  is	  how	  HLA-­‐B27,	  the	  strongest	  risk	  factor	  for	  AS,	  fits	  in	  this	  
story.	   Since	   HLA-­‐B27	   is	   an	   MCH	   class	   I	   molecule	   it	   will	   present	   endogenous	   antigens/peptides	  
originating	  from	  the	  cytoplasm	  on	  the	  cell	  surface.	  These	  antigens/peptides	  do	  not	  only	  include	  self-­‐
peptides	  but	  can	  also	  derive	  from	  viruses	  and	  bacteria.	  This	  peptide	  presentation	  could	  then	  possibly	  
be	  the	  link	  to	  the	  gut	  microbiome.	  As	  the	  HLA-­‐B27	  gene	  is	  not	  linked	  to	  IBD,	  another	  possibility	  is	  that	  
HLA-­‐B27	  does	  not	  play	  a	  role	  in	  disease	  induction	  in	  the	  gut,	  but	  only	  plays	  a	  role	  in	  inflammation	  at	  
the	  joint	  level.	  Another	  question	  is	  how	  to	  explain	  joint	  inflammation	  in	  AS	  patients	  without	  currently	  
detectable	   gut	   inflammation.	   	   Notwithstanding	   the	   many	   additional	   questions,	   the	   paradigm	  
proposed	   by	   Ciccia	   et	   al	   focusing	   on	   ILC3	   cells	   as	   cytokine	   shuttle	   travelling	   from	   gut	   to	   blood,	  
synovium	   and	   bone	   marrow	   in	   AS	   is	   an	   interesting	   new	   approach	   to	   the	   unraveling	   of	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